Table 5. DFS of the stage I-III CRC patients (Cohort II).
| Variables | Cases (n = 146) | 5-year DFS (%) | DFS (months) Mean ± S.D. | Univariate P value | Multivariate P value |
|---|---|---|---|---|---|
| Gender | 0.120 | ||||
| Female | 50 | 89.0% | 105.3 ± 6.1 | ||
| Male | 96 | 82.7% | 91.6 ± 4.2 | ||
| Age (year) | 0.647 | ||||
| <60 | 73 | 87.4% | 98.6 ± 4.9 | ||
| ≥60 | 73 | 81.5% | 94.5 ± 5.7 | ||
| Preoperative CEA level | 0.078 | ||||
| <100 ng/ml | 70 | 88.2% | 101.6 ± 4.2 | ||
| ≥100 ng/ml | 76 | 81.0% | 90.8 ± 5.6 | ||
| Tumor location | 0.063 | ||||
| Colon | 98 | 86.6% | 102.3 ± 4.4 | ||
| Rectum | 48 | 80.6% | 89.7 ± 5.0 | ||
| Tumor size | <0.001* | 0.001* | |||
| <5 cm | 69 | 90.4% | 102.5 ± 5.2 | ||
| ≥5 cm | 77 | 76.6% | 85.0 ± 4.9 | ||
| Tumor differentiation | 0.591 | ||||
| Poor | 34 | 84.6% | 98.0 ± 6.4 | ||
| Well/Moderate | 112 | 84.3% | 95.9 ± 4.6 | ||
| TNM stage | 0.174 | ||||
| I-II | 88 | 85.5% | 99.7 ± 4.4 | ||
| III | 58 | 83.1% | 83.2 ± 5.0 | ||
| Adjunctive chemotherapy | 0.869 | ||||
| No | 100 | 82.0% | 96.9 ± 4.4 | ||
| Yes | 46 | 91.2% | 87.8 ± 5.0 | ||
| TBL1XR1 expression | <0.001* | <0.001* | |||
| Low | 87 | 93.2% | 106.4 ± 4.1 | ||
| High | 59 | 70.6% | 77.1 ± 5.4 |
Abbreviations: TBL1XR1, Transducin (β)-like 1 X-linked receptor 1; CRC, colorectal cancer.